Gilead Reports Strong Q3 2026, Raises Full-Year Base Business Revenue Guidance Again

What happened

Gilead Sciences announced Q3 2026 results on October 29, 2026, with CEO Daniel O'Day characterizing the quarter as exceptional and noting the strongest year-over-year base business growth in more than a decade. This performance led management to raise full-year base business revenue guidance for the second time, signaling that core operations—particularly HIV and the Yeztugo launch—are exceeding prior expectations. The announcement aligns with the DeepValue thesis that Yeztugo's payer coverage conversion and HIV franchise durability would drive growth, and suggests the bear case of stalled utilization is becoming less likely. However, the press release does not provide specific financial figures for Q3, so the magnitude of the beat and the exact contribution of Yeztugo versus Biktarvy remain unconfirmed. Investors should monitor the upcoming 10-Q filing for details on Yeztugo quarterly sales (the prior threshold was $250M to increase conviction) and any updates on the acquired IPR&D charge impact that still clouds GAAP profitability.

Implication

The strong base business growth and guidance raise reduce downside risk and increase the probability of the bull scenario, potentially pushing fair value toward the $150+ range if Yeztugo trends are confirmed. Investors should look for Q3 Yeztugo sales exceeding $250 million and sustained payer coverage at ~90%, as these were explicit trigger points for increasing conviction in the DeepValue framework. The lack of disclosed GAAP earnings impact means the full-year 2026 net loss expectation from acquisition charges remains intact, so the valuation discount may persist until charge noise clears. If Q3 results validate the HIV prevention ramp, the next catalyst to watch is the BIC/LEN approval (PDUFA Aug 27, 2026, already past) and the anito-cel PDUFA on Dec 23, 2026, which could extend momentum. For long-term investors, the raised guidance supports the base case of HIV durability and Yeztugo scaling, but near-term price action may still be capped by the GAAP loss optics and execution risk in oncology.

Thesis delta

The Q3 announcement reinforces the core thesis that HIV cash flows and Yeztugo adoption are strengthening, with management explicitly raising full-year base business revenue guidance again. This shift moves the risk/reward from 'potential buy' toward 'confirmed buy' if Yeztugo sales exceed the $250M quarterly threshold. However, the thesis remains contingent on seeing actual quarterly numbers for Yeztugo and confirmation that acquisition-related charges are contained to the guided ~$11.5B.